You are here

  • Home
  • Archive
  • Volume 75, Issue Suppl 2
  • FRI0182 A Single Dose Study Comparing Pharmacokinetics, Safety, and Immunogenicity of M923 (A Proposed Biosimilar To Adalimumab), US-Sourced Adalimumab, and EU-Sourced Adalimumab in Healthy Subjects

Article metrics

Article menu
Download PDFPDF
Poster Presentations
Rheumatoid arthritis - anti-TNF therapy
FRI0182 A Single Dose Study Comparing Pharmacokinetics, Safety, and Immunogenicity of M923 (A Proposed Biosimilar To Adalimumab), US-Sourced Adalimumab, and EU-Sourced Adalimumab in Healthy Subjects

 

Online download statistics by month:

Online download statistics by month: July 2016 to March 2024

AbstractFullPdf
Jul 2016400
Aug 2016702
Sep 2016502
Oct 2016900
Nov 20162704
Dec 20161600
Jan 20171001
Feb 20171501
Mar 2017701
Apr 20172701
May 20171904
Jun 20172001
Jul 20173003
Aug 20175406
Sep 20173003
Oct 20173002
Nov 20171400
Dec 20172001
Jan 20181600
Feb 20182500
Mar 20181000
Apr 2018800
May 20181600
Jun 2018800
Jul 20181400
Aug 20181000
Sep 20181200
Oct 2018400
Nov 20181000
Dec 20182000
Jan 2019600
Feb 2019400
Mar 2019200
Apr 2019200
May 2019400
Jun 2019800
Jul 2019900
Aug 2019400
Nov 20191000
Dec 2019400
Feb 2020500
Mar 2020200
Apr 20201600
Jun 2020400
Jul 20201201
Aug 2020600
Sep 20202200
Oct 2020200
Nov 20201000
Dec 2020400
Jan 2021801
Mar 2021200
Apr 2021600
Jun 2021100
Oct 2021200
Nov 20211201
Dec 2021800
Jan 2022200
Feb 2022200
Mar 2022400
May 20221000
Jun 2022200
Jul 20221000
Aug 2022800
Sep 2022400
Oct 2022800
Nov 20223901
Dec 20222000
Jan 2023800
Feb 20231000
Mar 20231901
Apr 20231400
May 20231200
Jun 2023500
Jul 2023800
Aug 2023300
Sep 2023800
Oct 20231601
Nov 20231400
Dec 20232000
Jan 2024200
Feb 20241600
Mar 20241801
Total954039